Industry Insights
Epigenetics Optimized Cell Culture Conditions To Drive and Maintain Cell Identity
Industry InsightTechnology Networks spoke with Pierre-Louis Joffrin, corporate development officer at Mogrify, to learn more about the EpiMOGRIFY platform, the advantages of using a data-driven method to maintain cell identity and support cell conversion, and the implications this could have for the development of cell therapies.
Read More
3 Major Trends for Cardiac Drug Discovery in 2020
Industry InsightWithout a doubt, we will remember 2020 as the year of the COVID-19 pandemic. For the biopharma and healthcare sectors, the focus was firmly on the rapid development of diagnostics, therapies and vaccines that could be produced at scale. But under the radar, other life science fields have been powering on – among them, the cardiac field.
Read More
Planning for 2021: Three Lessons the Clinical Development Sector Can Learn From 2020
Industry InsightThe clinical trials industry, like many other global sectors, has been hit hard by the pandemic. One outcome has been the necessary diversion of resources to the development of COVID-19 vaccines and treatments alongside the care of critically ill patients. Impending economic contraction around the world means trials are also taking place against a backdrop of tighter budgets, leaving clinical development on a cliff edge as 2021 approaches.
Cell Replacement Therapy – A Promising Treatment for Age-Related Macular Degeneration
Industry InsightHere we share a Q&A with Brian Culley, CEO of Lineage Cell Therapeutics. In this interview, Brian discusses age-related macular degeneration and retinal pigment epithelium transplant therapy.
Read More
Collaboration Is the Key to Efficient Product Development
Industry InsightOutsourcing certain aspects of experimental work to biotech companies with vital experience in relevant areas can help to advance products more rapidly, accelerating time-to-market and ensuring success.
Read More
A Vaccine for Alzheimer’s Disease? An Interview With AC Immune’s Prof Andrea Pfeifer
Industry InsightSwiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. 2020 has brought mixed news for AC Immune's therapeutics, including promising safety data for their anti-Alzheimer's disease vaccine candidate. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.
Read More
Overcoming the Challenges of Manufacturing Therapeutic Mesenchymal Stem Cells
Industry InsightTechnology Networks had the pleasure of speaking with Ross Macdonald, CEO of Cynata Therapeutics, to learn more about the challenges of manufacturing therapeutic MSCs and how the Cymerus technology overcomes these.
Read More
Could DMT-Assisted Therapy Help Treat Mental Health Disorders?
Industry InsightThe role that psychedelic therapeutics could play in tackling many intractable mental health conditions has finally been recognized by mainstream medicine. To find out more, we spoke to Carol Routledge, Chief Medical & Scientific Officer at Small Pharma.
Read More
Ensuring Data Integrity Compliance in Pharma With CDS Software
Industry InsightData integrity is fundamental to drug development and manufacturing but can be difficult to achieve for drug developers and manufacturers who have to navigate strict data integrity guidelines provided by regulatory authorities and find effective ways to attain compliance.
Read More
Cell and Gene Therapy Manufacturing: Achieving Consistency and Reducing Variability
Industry InsightCell and gene therapies first gained regulatory approval in 2017 by the US Food and Drug Administration (FDA). Several more therapies have since been developed, and there are now 18 approved to treat a variety of diseases Technology Networks recently had the pleasure of speaking with experts at Bio-Techne to learn more about the cell and gene therapy manufacturing process.
Read More
